Palexia RP (tapentadol extended release) / Assertio, Collegium Pharma, Grunenthal, J&J  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
2009-017470-20: An open-label extension study for patients with severe chronic low back pain or severe chronic pain due to knee osteoarthritis who have completed any of the previous phase IIIb trials with tapentadol hydrochloride, KF5503/42, KF5503/44 or KF5503/45.

Ongoing
3
25
Europe
Tapentadol 50 mg film coated tablet, Tapentadol 50 mg prolonged release tablet, Tapentadol 100 mg prolonged release tablet, Tapentadol 150 mg prolonged release tablet, Tapentadol 200 mg prolonged release tablet, Tapentadol 250 mg prolonged release tablet, CG5503,
Laboratoires Grünenthal
Severe chronic pain
 
 
2022-001358-41: Clinical study to prove that treatment of chronic (non-specific) low back pain with VER-01, a cannabis based medicine, shows benefit compared to treatment with opioids

Not yet recruiting
3
350
Europe
Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype, Tilidine and Naloxone (50 mg/4 mg) prolonged-release tablets, Tilidine and Naloxone (100 mg/8 mg) prolonged-release tablets, Tramadol 100 mg prolonged-release tablets, Tramadol 200 mg prolonged-release tablets, Fentanyl 12 micrograms/h transdermal patch, Fentanyl 25 micrograms/h transdermal patch, Fentanyl 50 micrograms/h transdermal patch, Oxycodone 5 mg prolonged-release tablets, Oxycodone 20 mg prolonged-release tablets, Oxycodone & Naloxone (5 mg/2.5 mg) prolonged-release tablets, Oxycodone & Naloxone (20 mg/10 mg) prolonged-release tablets, Hydromorphone 4 mg Prolonged Release tablets, Hydromorphone 8 mg Prolonged Release tablets, Morphine 10 mg prolonged-release tablets, Morphine 20 mg prolonged-release tablets, Tapentadol 50 mg prolonged-release tablets, Tapentadol 100 mg prolonged-release tablets, Buprenorphine 5 µg/h Transdermal Patch, Buprenorphine 15 µg/h Transdermal Patch, Buprenorphine 35 µg/h Transdermal Patch, VER-01, NA, Not Applicable, Oral solution, Prolonged-release tablet, Transdermal patch
Vertanical GmbH, Vertanical GmbH
Chronic non-specific low back pain, Back pain in between the lower edge of the ribs and the lower fold of the buttocks lasting for at least 3 months which has no specific identifiable cause, Diseases [C] - Musculoskeletal Diseases [C05]
 
 

Download Options